TITLE

Too few joint patients get clot busting drugs after discharge

AUTHOR(S)
Spurgeon, David
PUB. DATE
June 2008
SOURCE
BMJ: British Medical Journal (International Edition);6/14/2008, Vol. 336 Issue 7657, p1330
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on research which was published in the "Canadian Medical Association Journal". The research found that less than one in five elderly patients in Canada received anticoagulants after discharge from hospitals following hip or knee replacement surgery, and that such patients are at high risk of developing venous thromboembolism. The research also indicated that patients who were prescribed anticoagulants had a lower risk of short term mortality, and that additional research was needed on the benefits of and barriers to thromboprophylaxis after discharge from hospitals.
ACCESSION #
32743946

 

Related Articles

  • FDA Drug Approvals. . New molecular entities.  // Formulary;Oct2011, Vol. 46 Issue 10, p400 

    The article reports on 2011 research which the U.S. Food & Drug Administration has conducted on the safety and efficacy of drugs, including Xarelto and Brilinta, which are considered new molecular entities. A discussion of approval which the agency gave for the use of the drugs after conducting...

  • A 12 month review of a modified protocol using low dose Dabigatran Etexilate in postoperative thromboembolic prophylaxis in joint replacement surgery. Subramanian, Padmanabhan; Kantharuban, Shanjitha; Shilston, Sophie; Pearce, Oliver James // Thrombosis Journal;2012, Vol. 10 Issue 1, p14 

    Background: Venous Thrombo-embolic disease is currently a hot topic especially in the UK. 25,000 patients per year die of Pulmonary Emboli (PE) in the United Kingdom (UK). Hip and knee arthroplasty surgery is associated with an increased rate of deep vein thrombosis (DVT) and pulmonary embolus...

  • Rivaroxaban. Duggan, Sean T.; Scott, Lesley J.; Plosker, Greg L. // Drugs;2009, Vol. 69 Issue 13, p1829 

    Rivaroxaban (Xarelto®), an oral oxazolidinone-based anticoagulant, is a potent, selective direct inhibitor of factor Xa that is used in the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery. In four large,...

  • Rivaroxaban rates in Russia for preventing VTE after surgery.  // PharmacoEconomics & Outcomes News;6/11/2011, Issue 630, p4 

    The article deals with two studies which examine the effectiveness of rivaroxaban compared with dabigatran and enoxaparin for the prevention of venous thromboembolism after total hip and total knee replacement, presented at the 16th Annual International Meeting of the International Society for...

  • High complication rate after total knee and hip replacement due to perioperative bridging of anticoagulant therapy based on the 2012 ACCP guideline. Leijtens, Borg; Kremers van de Hei, Keetie; Jansen, Justus; Koëter, Sander // Archives of Orthopaedic & Trauma Surgery;Sep2014, Vol. 134 Issue 9, p1335 

    Introduction: An increasing amount of patients receiving total joint replacement require bridging of long-term anticoagulants. Guidelines, aimed at preventing complications, focus on thromboembolic events but not on bleeding complications. In this retrospective observational study, bleeding and...

  • Pharmacological thromboprophylaxis and total hip or knee replacement. Frostick, Simon // British Journal of Nursing;1/14/2016, Vol. 25 Issue 1, p45 

    Pharmacological and mechanical thromboprophylaxis reduces the risk of venous thromboembolism (VTE) in patients undergoing total knee/hip replacement (TKR/THR). Nurses play a key role in VTE prevention through clinical care, before and after discharge from hospital, and patient education....

  • Clinical Focus - Hip and knee replacements.  // Independent Nurse;3/12/2010, p1 

    The article provides information on types of hip and knee replacements, complications and outcomes of joint replacement and revision surgery. It states the major risk referred to as thromboembolism in hip replacement, systemic complications of knee and hip replacements and the most common...

  • New oral anticoagulants: Their impact on efficacy and safety in patients undergoing total hip and total knee replacement and their influence on postoperative management. Fisher, William D. // Formulary;May2012, Vol. 47 Issue 5, p197 

    With the aging of the US population, elective total hip and knee replacement operations have become more prevalent, and costs to the healthcare system for these procedures are increasing rapidly. This includes costs related to treatment of venous thromboembolism, which may be a consequence of...

  • Anticoagulation Bridging Therapy after Total Hip or Knee Replacement: A Missed Opportunity? Collins, Jr., Charles E. // American Health & Drug Benefits;Jul2011, Vol. 4 Issue 4, p248 

    In this article the author discusses an article which investigated the use of anticoagulation bridging therapy after total hip or knee replacements. He is supportive of the results of research which is discussed in the article and of the use of anticoagulation bridging therapy after total hip or...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics